Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy

Nephron - Clinical Practice

Volumn 96, Issue 3, 2004, Pages

  Westall, Glen P ^a   Binder, John ^c   Kotsimbos, Tom ^a   Topliss, Duncan ^a   Thomson, Napier ^a   Dowling, John ^b   Wilson, John W ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c TOWNSVILLE HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Cystic fibrosis; Diabetes mellitus; Kimmelstiel Wilson nodules; Nodular glomerulosclerosis

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COHORT ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ELECTRON MICROSCOPY; GENE MUTATION; GENOTYPE; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMPAIRED GLUCOSE TOLERANCE; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LABORATORY TEST; MALE; OPHTHALMOSCOPY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SWEAT TEST; URINALYSIS;

ADULT; CYSTIC FIBROSIS; DIABETIC NEPHROPATHIES; DIAGNOSIS, DIFFERENTIAL; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MALE; MICROSCOPY, ELECTRON;

EID: 1842611661     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076743     Document Type: Article

References (33)

1. Tsui L, Buchwald M, Barker D, Barker D, Braman JC, Knowlton R, Schumm JW, Eiberg H, Mohr J, Kennedy D, Plavsic N, et al: Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985;239:1054-1057.
2. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ: Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991;253:202-205.
3. Kulczycki LL, Kostuch M, Bellanti JA: A clinical perspective of cystic fibrosis and new genetic findings: Relationship of CFTR mutations to genotype-phenotype manifestations. Am J Med Genet 2003;116A:262-267.
4. Moran AM, Doherty L, Wang X, Thomas W: Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998;133:10-17.
5. Milla CE, Warwick WJ, Moran A: Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-895.
6. Lanng S, Thorsteinson B, Nerup J, Koch C: Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992;151:684-687.
7. Kimmelstiel P, Wilson C: Intracapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-97.
8. Bell ET: Renal vascular disease in diabetes mellitus. Diabetes 1953;2:376-389.
9. Herzenberg AM, Holden JK, Singh S, Magil AB: Idiopathic nodular glomerulosclerosis. Am J Kidney Dis 1999;34:560-564.
10. Preud'homme J-L, Aucouturier P, Touchard G, Striker L, Khamlichi AA, Rocca A, Denoroy L, Cogne M: Monoclonal immunoglobulin deposition disease (Randall type): Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994;46:965-972.
11. Sanders PW, Herrera G, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991;64:527-537.
12. Alpers CE, Magil AB, Biava CG: Fibrillary glomerulonephritis. Prog Reprod Urin Tract Pathol 1989;1:197-212.
13. McCarty NA: Permeation through the CFTR chloride channel. J Exp Biol 2000;203:1947-1962.
14. Alpers CE, Biava CG: Idiopathic lobular glomerulonephritis (nodular mesangial sclerosis): A distinct diagnostic entity. Clin Nephrol 1989;32:68-74.
15. Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D'Agati VD: Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002;33:826-835.
16. Brownlee M, Cerami A, Vlassara H: Advanced glcosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
17. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA: Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging and uremia. Diabetes 1992;41:36-41.
18. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955.
19. Kent MJC, Light ND, Bailey AJ: Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 1985;225:745-752.
20. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881-1887.
21. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822-832.
22. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/ calgranulin polypeptides. Cell 1999;97:889-901.
23. Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK: The leucocyte L1 protein: Identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1998;28:241-245.
24. Foell D, Seeliger S, Vogl T, Koch H-G, Maschek H, Harms E, Sorg C, Roth J: Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003;58:613-617.
25. Lal MA, Brismar H, Eklof A, Aperia A: Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002;61:2006-2014.
26. Anderson MM, Requena JR, Crowley JR, Thorper SR, Heineche JW: The myeloperoxidase system of human phagocytes generates NAε-(carboxymethyl) lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-113.
27. Linsdell P, Hanrahan JW: Glutathione permeability of CFTR. Am J Physiol 1998;275:C323-C326.
28. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
29. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and ageing complications. Proc Natl Acad Sci USA 1992;89:12043-12047.
30. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C: Glucose tolerance in patients with cystic fibrosis: Five year prospective study. BMJ 1995;311:655-659.
31. Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, Magazzu G, Raimndo G, Arrigo T: Factors affecting diabetes mellitus onset in cystic fibrosis: Evidence from a 10-year follow-up study. Acta Paediatr 1999;88:389-393.
32. Scanlin TF, Glick MC: Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta 1999;1455:241-253.
33. Hill WG, Harper GS, Rozaklis T, Boucher RC, Hopwood JJ: Organ-specific over-sulfation of glycosaminoglycans and altered extracellular matrix in a mouse model of cystic fibrosis. Biochem Mol Med 1997;62:113-122.